Pacific Biosciences

PACB

Market cap $700M

MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at Piper Sandler's 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 11:30 AM ET in New York, NY.

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PacBio posts a narrower Q3 loss and margin gains, but shares fall as revenues dip amid softer instrument demand.

Pacific Biosciences of California, Inc. ( PACB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Christian Henry - President, CEO & Director James Gibson - Chief Financial Officer Conference Call Participants Carrie Mendivil - Gilmartin Group LLC Kyle Mikson - Canaccord Genuity Corp., Research Division Madeline Mollman - Wolfe Research, LLC Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Benjamin Mee - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Nathan Bolanos - UBS Investment Bank, Research Division Presentation Operator Good day, and welcome to the PacBio Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Although the revenue and EPS for Pacific Biosciences (PACB) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.17 per share a year ago.

New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Pacific Biosciences (PACB), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia